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ABSTRACT
Background
Availability of an ultra-short-course drug regimen capable of curing patients with
tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because
immediate prospects for novel treatment-shortening drugs remain uncertain, we examined
whether better use of existing drugs could shorten the duration of treatment. Rifapentine is a
long-lived rifamycin derivative currently recommended only in once-weekly continuation-
phase regimens. Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line
regimens.
Methods and Findings
Using a well-established mouse model with a high bacterial burden and human-equivalent
drug dosing, we compared the efficacy of rifapentine- and moxifloxacin-containing regimens
with that of the standard daily short-course regimen based on rifampin, isoniazid, and
pyrazinamide. Bactericidal activity was assessed by lung colony-forming unit counts, and
sterilizing activity was assessed by the proportion of mice with culture-positive relapse after 2,
3, 4, and 6 mo of treatment. Here, we demonstrate that replacing rifampin with rifapentine and
isoniazid with moxifloxacin dramatically increased the activity of the standard daily regimen.
After just 2 mo of treatment, mice receiving rifapentine- and moxifloxacin-containing regimens
were found to have negative lung cultures, while those given the standard regimen still
harbored 3.17 log10 colony-forming units in the lungs (p , 0.01). No relapse was observed after
just 3 mo of treatment with daily and thrice-weekly administered rifapentine- and moxifloxacin-
containing regimens, whereas the standard daily regimen required 6 mo to prevent relapse in
all mice.
Conclusions
Rifapentine should no longer be viewed solely as a rifamycin for once-weekly administration.
Our results suggest that treatment regimens based on daily and thrice-weekly administration of
rifapentine and moxifloxacin may permit shortening the current 6 mo duration of treatment to
3 mo or less. Such regimens warrant urgent clinical investigation.
The Editors’ Summary of this article follows the references.
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The development of simpliﬁed treatment regimens is a
major priority of the Global Plan to Stop TB [1]. Novel
regimens that are substantially shorter than the current 6-mo
regimen are expected to simplify tuberculosis (TB) treatment,
facilitate global implementation of directly observed therapy,
improve treatment completion rates, and limit the emer-
gence of multidrug-resistant TB.
It is widely believed that shortening the duration of TB
therapy will require the development of new drugs with novel
mechanisms of action [2]. Indeed, there is great optimism
over several novel drug candidates that have recently entered
Phase I and Phase II testing exclusively for the treatment of
TB [3]. However, the immediate prospects for inclusion of
these candidates into a new regimen remain uncertain. For
example, TMC-207 has been highly regarded as a candidate
for shortening therapy [4], but is currently being developed as
a drug for multidrug-resistant TB rather than for drug-
susceptible disease, at least in part due to a drug–drug
interaction with rifampin. One recent analysis predicted the
likelihood of introducing at least one successful anti-TB drug
by 2010 to be ,5% and the likelihood of introducing a novel
regimen with at least two new drugs to be ,1% [5].
Therefore, it is critical that existing drugs should be used in
ways that optimize their potential activity.
Rifampin is recognized as the most important sterilizing
drug in the modern short-course regimen. However, rifampin
has a relatively short half-life of 2–4 h [6]. Rifampin-based
regimens are less effective when the standard 600-mg daily
dose is administered twice- or thrice-weekly as opposed to
daily [7], and attempts to increase the rifampin dose to 1,200
mg or more in once- or twice-weekly regimens frequently
result in an inﬂuenza-like syndrome [8–10]. Rifapentine is a
cyclopentyl-substituted rifamycin which has been approved
for use against TB in the United States since 1998 [11].
Because its half-life is ﬁve times longer than that of rifampin,
it was developed as a rifamycin for once-weekly adminis-
tration [12]. However, once-weekly treatment with rifapen-
tine (600 mg) and isoniazid during the continuation phase of
treatment, while effective, is inferior to twice- or thrice-
weekly treatment with rifampin (600 mg) and isoniazid in
patients at high risk of treatment failure and relapse, and
current recommendations limit its use to HIV-seronegative
persons with non-cavitary TB [11–14].
Low rifamycin drug exposure might explain the suboptimal
efﬁcacy of once-weekly rifapentine-containing regimens,
particularly in the light of rifapentine’s high protein binding
[6,12,15,16]. On the supposition that the bactericidal activity
of the rifamycins is correlated with the area under the serum
concentration versus time curve divided by the minimum
inhibitory concentration (AUC/MIC) [6,17,18], more frequent
administration of rifapentine, with or without the use of
higher doses, could greatly increase the rifamycin exposure
over that obtained with 600 mg once per week and could
result in substantially more potent treatment regimens (18).
Rifapentine is well tolerated when administered once-weekly
at doses of up to 1,200 mg and twice-weekly at doses of up to
600 mg [11,19,20]. The tolerability and safety of higher or
more frequent doses have not been rigorously assessed. On
the other hand, owing to concerns over the inﬂuenza-like
syndrome and other adverse effects, there is reluctance to use
rifampin at doses higher than 600 mg, especially with
intermittent administration. In this context, we assessed the
treatment-shortening potential of daily and intermittent
treatment regimens with more frequent administration of
rifapentine to signiﬁcantly increase rifamycin exposure.
Because we had previously demonstrated that the substitu-
tion of moxiﬂoxacin for isoniazid substantially increases the
bactericidal activity of rifamycin-based regimens [21,22], we
also included this substitution in our test regimens.
Methods
Antimicrobials
Moxiﬂoxacin (M) was kindly provided by Bayer Pharma-
ceuticals, isoniazid (H) and rifampin (R) were purchased from
Sigma, and pyrazinamide (Z) was purchased from Fisher
Scientiﬁc International. All drugs were either dissolved or
suspended in water prior to oral gavage. Rifapentine (P)
tablets, donated by Sanoﬁ-Aventis, were ground into a ﬁne
powder, suspended in water, and brieﬂy sonicated before
gavage. Drug solutions were prepared weekly and stored at 4
8C.
Aerosol Infection
Six-week-old BALB/c mice (Charles River) were aerosol
infected with Mycobacterium tuberculosis H37Rv using the
Middlebrook inhalation exposure system (Glas-Col) with a
log-phase broth culture. All animal procedures were ap-
proved by the Johns Hopkins University Animal Care and Use
Committee.
Chemotherapy
Treatment began 15 d after infection (on D0) in the ﬁrst
chemotherapeutic study (Table 1; Figure 1). Drugs were
administered by oral gavage either 7 d/wk (7/7), 5 d/wk (5/7), 3
d/wk (3/7), or 2 d/wk (2/7) in the following doses: isoniazid (H),
25 mg/kg; rifampin (R), 10 mg/kg; pyrazinamide (Z), 150 mg/kg
when administered (7/7) or (5/7), 225 mg/kg when adminis-
tered (3/7), and 300 mg/kg when administered (2/7); moxi-
ﬂoxacin (M), 100 mg/kg twice per day; rifapentine, 7.5, 10, 15,
and 20 mg/kg as indicated by the subscript numbers
accompanying the abbreviation for the drug. Dosages for H,
R, Z, and M were chosen to produce a serum AUC in mice
equivalent to the AUC obtained with currently recommended
human dosages [23,24]. For P, the 7.5-, 10-, 15-, and 20-mg/kg
dosages are equivalent to 450-, 600-, 900-, and 1,200-mg
dosages in humans, respectively [24].
At the start of treatment (D0), mice were block-randomized
(by infection run) into eight groups (Table 1). Negative
control mice went untreated, and positive control mice
received standard daily (5/7) therapy (2 mo of rifampin plus
isoniazid plus pyrazinamide [RHZ] followed by 2, 3, or 4 mo
of RH) or 2 mo of twice-weekly P15MZ followed by 2 mo of
twice-weekly P15M. To assess the impact of increasing the P
dose, mice in Test Group 4 received 2 mo of P20MZ (2/7)
followed by 1 mo of P20M (2/7). To assess the impact of
increasing the frequency of drug administration to thrice-
weekly, mice in Test Group 5 received 2 mo of P15MZ (3/7)
followed by 1 mo of P15M (3/7). To assess the impact of
increasing the frequency of drug administration to 5 d/wk,
Test Groups 6 and 7 received 2 mo of rifapentine plus
moxiﬂoxacin plus pyrazinamide (PMZ) (5/7) followed by 1 mo
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respectively. Test Group 8 received true daily therapy with 2
mo of P10MZ (7/7).
In the second chemotherapeutic study (Figure 2), treatment
began 14 d after infection (D0) with M. tuberculosis H37Rv.
Mice were treated with daily (5/7) R10HZ, R10MZ, P10HZ, and
P10MZ for 2, 4, 6, or 10 wk.
Assessment of Treatment Efficacy
Treatment efﬁcacy was assessed on the bases of lung
colony-forming unit (CFU) counts and the proportion of
mice with culture-positive relapse after treatment comple-
tion. To monitor the bacterial multiplication and establish
baseline CFU counts prior to treatment, untreated mice were
humanely killed the day after aerosol infection, with others
killed 14 d later (D0), at the initiation of treatment.
Subsequently, mice from all treatment groups were killed
during treatment to assess bactericidal activity. Lungs were
removed under aseptic conditions, placed in phosphate-
buffered saline, homogenized, and plated on 7H11 agar
enriched with 10% oleic acid-albumin-dextrose-catalase and
supplemented with cycloheximide (10 lg/ml), carbenicillin
(50 lg/ml), polymyxin B (25 lg/ml), and trimethoprim (20 lg/
ml) to prevent contamination. Plates were incubated for 28 d
at 37 8C in a 5% CO2 environment before CFU counts were
determined.
The proportion of culture-positive mice was determined by
humanely killing a cohort of mice 3 mo after the completion
of treatment. Mice were considered to be culture-positive if
 1 CFU was identiﬁed after plating the entire lung
homogenate. In chemotherapy study 1 (Figure 1; Table 1),
the proportion of mice with culture-positive relapse was
determined after 2 and 3 mo of treatment for mice receiving
the experimental regimens, and after 3, 4, and 6 mo for mice
receiving the control regimens. In chemotherapy study 2
(Figure 2), the proportion of culture-positive mice was
determined after 10 wk of treatment.
Pharmacokinetic and Pharmacodynamic Analyses
Rifamycin pharmacokinetics were determined in unin-
fected female Swiss Webster mice after oral gavage with single
doses of R10,P 7.5,P 10,P 15, and P20. Drug concentrations in
mouse plasma were determined by validated HPLC assays.
Single-dose serum-concentration time curves were deter-
mined using non-compartmental techniques (WinNonLin
Software). Steady-state pharmacokinetics assuming no auto-
induction were simulated using nonparametric superposi-
tion, followed by simulation using a one-compartment model
with ﬁrst-order elimination. Parameter estimates (absorption
rate constant, volume of distribution, and elimination rate
constant) were adjusted to match the median single-dose
serum-concentration time curve measured in mice, followed
by simulation of various doses and frequencies of admin-
istration. Simulated pharmacokinetic parameter estimates
were compared to actual published and unpublished steady-
state concentrations determined for selected twice-daily and
daily (5/7) regimens and showed excellent concordance [18].
Pharmacodynamic indices (e.g., free drug weekly AUC/MIC
and maximum serum concentration [Cmax]/MIC ratios and
time above MIC per week) were derived using the following
MIC values: rifapentine, 0.06 lg/ml; rifampin, 0.25 lg/ml [25].
Free drug concentrations were estimated to be 2.5% and
17.5% of total serum concentrations for rifapentine and
rifampin, respectively [6,11,17].
Statistical Analyses
CFU counts were log10 transformed before analysis and
expressed as CFU log10 6 standard error. Mean CFU counts
were compared using one-way ANOVA followed by Dunnett’s
multiple comparison test (Stata 8.2). The proportions of mice
relapsing after completing treatment were compared using
Fisher’s Exact test. Bonferroni’s procedure was used to adjust
the type I error rate for multiple comparisons.
Results
High-Dose Aerosol Infection with M. tuberculosis
In the ﬁrst chemotherapeutic study, mice were aerosol
infected with M. tuberculosis H37Rv in four separate runs. The
day after infection (day 14), mice harbored 4.29 6 0.04
tubercle bacilli per lung. Fourteen days later, at the start of
treatment (D0), the mean lung log10 CFU counts increased to
7.73 6 0.04, 7.56 6 0.12, 7.62 6 0.11, and 7.56 6 0.04 (p ¼
0.12, one-way ANOVA) for mice infected during infection
runs 1 to 4, respectively, indicating that all mice started
treatment with an equal number of tubercle bacilli implanted
Table 1. Scheme of Chemotherapy Experiment
Dosing Category Treatment Group
a Treatment Period after which Relapse Rates Were Determined
2 m o3 m o4 m o6 m o
Controls 1. Infected, untreated — — — —
2. 2 mo of R10HZ þ R10H (5/7) — — 33
3. 2 mo of P15MZ þ P15M (2/7) — 33—
Increased rifapentine dose 4. 2 mo of P20MZ þ P20M (2/7) 33——
Increased dosing frequency 5. 2 mo of P15MZ þ P15M (3/7) 33——
6. 2 mo of P7.5MZ þ P7.5M (5/7) 33——
7. 2 mo of P10MZ þ P10M (5/7) 33——
8. 2 mo of P10MZ (7/7) 3 ———
aBALB/c mice were aerosol infected with M. tuberculosis H37Rv and treated with regimens 2 to 8. Drugs were given orally at the following doses (in mg/kg): isoniazid (H), 25; rifampin (R),
10; pyrazinamide (Z), 150 mg/kg when administered 7 out of 7 d (7/7) or 5 out of 7 d (5/7), 225 mg/kg when administered 3 out of 7 d (3/7), and 300 mg/kg when administered 2 out of 7 d
(2/7) per week; moxifloxacin (M), 100 twice per day; rifapentine, 7.5, 10, 15, and 20 as indicated by the subscript numbers accompanying the abbreviation for the drug.3indicates 20 mice
assessed for relapse. Culture-positive relapse, as defined by the appearance of   1 CFU after plating the entire lung homogenate, was assessed 3 mo after completing 3, 4, and 6 mo of
treatment with the control regimens and 2 and 3 mo after completing treatment with the experimental regimens.
doi:10.1371/journal.pmed.0040344.t001
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humanely killed when they became moribund at 3 wk
postinfection.
Daily and Thrice-Weekly Rifapentine and Moxifloxacin-
Based Therapy Is More Active than Standard Therapy
At completion of the ﬁrst month of treatment, all
intermittent and daily PMZ regimens had signiﬁcantly greater
bactericidal activity than the standard daily (5/7) RHZ
regimen (Figure 1A). Compared to mice treated with RHZ
(5/7), those treated with PMZ-based regimens had lung CFU
counts that were between approximately 1 and 3 log10 lower
than those of mice treated with RHZ (5/7) (p , 0.01, Dunnett’s
multiple comparison test), and the extent of bactericidal
activity correlated with the frequency of drug administration
(Figure 1A).
After 2 mo of treatment, all mice receiving a PMZ-based
regimen had no detectable CFU, with the exception of two of
the ﬁve mice treated with twice-weekly P15MZ, which harbored
1 and 5 CFU per lung, respectively (Figure 1B). By contrast, all
mice treated with RHZ (5/7) remained culture positive with
3.17 log10 CFU per lung (p , 0.01, Dunnett’s multiple
comparison test). After 3 mo of treatment, all mice treated
with a PMZ-based regimen remained culture-negative, while
those treated with daily RHZ still harbored an average of 1.25
log10 CFU per lung (p , 0.01, Dunnett’s multiple comparison
test) (Figure 1C). All mice treated with daily RHZ were found
to be culture negative after 4 mo of treatment, with the
exception of one mouse which harbored 1 CFU per lung.
Thus, mice receiving any intermittent or daily PMZ-based
regimen other than P15MZ (2/7) achieved culture-negative
conversion 2 mo earlier than those receiving RHZ (5/7).
To further investigate the activity of the P10MZ (5/7)
regimen, we determined the individual contributions of P
and M on the regimen’s overall activity in a second chemo-
therapeutic study (Figure 2). The activity of the P10MZ (5/7)
regimen was compared to that of the standard daily regimen
of R10HZ (5/7), the well-characterized experimental regimen
of R10MZ (5/7) [21,22], and P10HZ (5/7). After only 2 wk of
therapy, treatment with P10MZ (5/7) was signiﬁcantly more
active than treatment with R10HZ, R10MZ, or P10HZ (p , 0.01,
Dunnett’s multiple comparison test), demonstrating the
improved initial bactericidal activity obtained by substituting
both P for R and M for H. After 6 wk of treatment with
R10HZ, mice still harbored more than 4.0 log10 CFU per lung,
whereas those treated with R10MZ and P10HZ harbored 2.28
Figure 1. Lung Log10 CFU Counts in M. tuberculosis–Infected Mice
CFU counts at treatment initiation (D0) and (A) after 1 mo, (B) after 2 mo,
and (C) after 3 mo of treatment. Data are presented as means and
standard error (error bars) (n¼five mice per time point). H, isoniazid; M,
moxifloxacin; Z, pyrazinamide; R, rifampin; P, rifapentine.
doi:10.1371/journal.pmed.0040344.g001
Figure 2. Bactericidal Activity of Daily (5/7) R10MZ, P10MZ, and P10HZ in
Comparison to Standard Daily Therapy with R10HZ in M. tuberculosis–
Infected Mice
Treatment began when the bacillary burden reached 7.45 6 0.03 log10
CFU per lung. After 10 wk of treatment and 3 mo of follow-up, the
proportion of mice that were lung culture–positive was 100% and 53%
for the R-containing regimens (R10HZ and R10MZ, respectively) and only
13% and 0% for the P-containing regimens (P10HZ and P10MZ,
respectively) (data not shown in Figure). H, isoniazid; M, moxifloxacin;
Z, pyrazinamide; R, rifampin; P, rifapentine.
doi:10.1371/journal.pmed.0040344.g002
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treated with P10MZ were completely lung culture–negative.
Therefore, in the standard regimen of R10HZ, the replace-
ment of R10 with P10 results in a signiﬁcantly greater increase
in bactericidal activity than the replacement of H with M (p ,
0.01, Dunnett’s multiple comparison test).
Rifapentine and Moxifloxacin-Based Therapy Produces
Stable Cure More Rapidly than Standard Therapy
To assess the duration of treatment required to achieve
stable cure, we determined the proportion of mice with
culture-positive relapse after the end of treatment (Table 2).
Although all PMZ regimens achieved lung culture conversion
following 2 mo of treatment, there were considerable differ-
ences in the proportion of mice with culture-positive relapse
at this time point (Table 2). In mice that received P10MZ (5/7)
and P10MZ (7/7), only 35% and 20% relapsed, respectively,
whereas 95% relapsed in groups receiving P20MZ twice-
weekly or P15MZ thrice-weekly (p , 0.01, Fisher’s Exact test).
The proportion of mice with culture-positive relapse after
treatment with daily P7.5MZ (5/7) was intermediate with 60%
of mice relapsing. Three months of treatment with thrice-
weekly or daily (5/7) regimens prevented relapse in all mice,
with the exception of one of 20 mice treated with P7.5MZ (5/7).
When PMZ was administered twice-weekly, 10%–20% of mice
relapsed, but these differences were not signiﬁcant when
compared with the thrice-weekly and daily PMZ-based
regimens (p ¼ 0.110, Fisher’s Exact test).
Relapse was not assessed in mice treated with the standard
control regimen, RHZ (5/7), until after 4 and 6 mo of
treatment, where 90% and 0% of mice relapsed, respectively.
Overall, these ﬁndings demonstrate that the duration of
treatment required to achieve 0% relapse was decreased by at
least 3 mo for the PMZ regimens administered daily or thrice-
weekly as compared to the duration required with the
standard daily regimen.
In the second chemotherapeutic study, we determined the
proportion of mice with positive cultures 3 mo after
completing 10 wk of treatment (Figure 2). Because lung
cultures were not performed to document culture-negative
conversion at the completion of treatment, we refrained from
labeling this outcome as ‘‘relapse.’’ After 10 wk of treatment
and 3 mo of follow-up, the proportion of mice that were lung
culture–positive was 100% (15/15) and 53% (8/15) for the R-
containing regimens (R10HZ and R10MZ, respectively) and
only 13% (2/15) and 0% (0/15) for the P-containing regimens
(P10HZ and P10MZ, respectively).
Rifapentine-Based Regimens Provide Enhanced Rifamycin
Exposure
Finally, in order to conﬁrm the increased rifamycin
exposure associated with P administration, we compared the
single-dose pharmacokinetic parameters (Figure 3) and the
simulatedsteady-statepharmacokineticandpharmacodynam-
ic parameters (Table 3) of intermittent and daily P admin-
istration, on the one hand, to those of daily R administration.
The area under the serum concentration versus time curve
(AUC0–48 h in lg-h/ml) for total drug concentrations after a
singledose of P was 341 6 33, 4176 61, 503 662, and 659 673
for7.5,10,15,and20mg/kg,respectively,comparedto116620
afterasingledoseof10mg/kgofR(p,0.01,Dunnett’smultiple
comparison test). The weekly area under the serum concen-
tration versus time curve (AUC0–168 h) for total drug concen-
trations at steady-state was between 2- and 4-fold higher for
intermittentanddailyP-basedregimenscomparedtothedaily
R10 regimen (Table 3). After adjusting for differences in the
minimuminhibitoryconcentration(MIC)andproteinbinding
between P and R, the rifamycin exposure, as measured by both
AUC0–168 h/MIC and the percentage of time above MIC per
week for free drug, remained much higher in the P-based
regimens (Table 3). Figure 4 depicts the simulated steady-state
pharmacodynamic curves based on free drug concentrations
for twice- and thrice-weekly, as well as daily (5/7, 7/7) P,
compared to daily (5/7) R10.
Discussion
We set out to determine whether two currently registered
drugs, rifapentine and moxiﬂoxacin, could be used more
effectively to improve the treatment of TB. Our results
Table 2. Culture-Positive Relapse Rates after Treatment with the
Standard Daily Regimen (RHZ) and with Intermittent and Daily
PMZ Regimens in M. tuberculosis–Infected Mice
Treatment
Group
a
Treatment Period after which Relapse Rates
Were Determined
2 m o3 m o 4 m o6 m o
2. R10HZ (5/7) ND
b ND
b 90% (18/20) 0% (0/20)
3. P15MZ (2/7) ND
c 10% (2/20) 0% (0/20) —
4. P20MZ (2/7) 95% (19/20) 20% (4/20) — —
5. P15MZ (3/7) 95% (19/20) 0% (0/20) — —
6. P7.5MZ (5/7) 60% (12/20) 5% (1/20) — —
7. P10MZ (5/7) 35% (7/20) 0% (0/20) — —
8. P10MZ (7/7) 20% (4/20) — — —
aZ administered for the first 2 mo of therapy only.
bAll five mice tested at treatment completion remained culture-positive.
cTwo of five mice tested at treatment completion remained culture-positive.
H, isoniazid; M, moxifloxacin; ND, not determined; P, rifapentine; R, rifampin; Z,
pyrazinamide.
doi:10.1371/journal.pmed.0040344.t002
Figure 3. Mean Rifapentine and Rifampin Serum Concentrations versus
Time
Mice were administered a single dose of 7.5, 10, 15, and 20 mg/kg of
rifapentine or 10 mg/kg of rifampin. P, rifapentine; R, rifampin.
doi:10.1371/journal.pmed.0040344.g003
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drug exposure by replacing rifampin with rifapentine and
replacing isoniazid with moxiﬂoxacin in the standard 6-mo
daily treatment regimen may radically shorten the duration
of therapy necessary to cure patients of TB. Treatment with
P7.5MZ and P10MZ 5 d/wk (5/7) eliminated M. tuberculosis bacilli
at a rate more than twice as fast as treatment with R10HZ (5/
7). During the ﬁrst month of treatment, the rates of kill were
1.17 and 1.31 log10 CFU/week for P7.5MZ and P10MZ (5/7),
respectively, versus 0.54 log10 CFU/week for the standard
control regimen (p , 0.01). All mice treated with PMZ (5/7)
had negative lung cultures after 2 mo of treatment, while
more than 4 mo was required to render all lung cultures
negative in mice treated with RHZ (5/7). Finally, the
proportion of mice relapsing after treatment with PMZ (5/7)
regimens was 19 out of 40 (47.5%) and one out of 40 (2.5%)
after 2 and 3 mo of treatment, respectively, compared to 18
out of 20 (90%) and 0 out of 20 (0%) after RHZ (5/7) for 4 and
6 mo, respectively. Relapse was not assessed after 5 mo of
treatment with RHZ (5/7) in this study, but comparisons with
other recent experiments in our model on the bases of the 4-
and 6-mo relapse rates suggest that the 5-mo relapse rate
would have been between 17% and 60% [18,24]. Therefore,
daily (5/7) treatment with the PMZ-based regimens may
permit the treatment duration to be reduced by at least 50%,
from 6 mo to 3 mo, without sacriﬁcing efﬁcacy.
The long serum half-lives of P and M also might enable
treatment-shortening regimens to be administered intermit-
tently as opposed to daily, thus further reducing the
resources necessary to administer supervised treatment [26].
To this end, decreasing the frequency of drug administration
from 5 d/wk to 3 d/wk in our study did not signiﬁcantly alter
the potency of the PMZ regimen, provided the dose of P was
increased from 7.5 mg/kg to 15 mg/kg. Administration of
P15MZ thrice-weekly (3/7) produced a rate of kill similar to
that of P7.5MZ (5/7) and prevented relapse in all mice after
just 3 mo of treatment. Decreasing the frequency of drug
administration to 2 d/wk resulted in reduced bactericidal
activity compared to daily PMZ-based regimens. Still, the
majority of mice receiving PMZ-based regimens twice-weekly
(2/7) were cured after 3 mo of treatment, although 4 mo was
required to prevent all relapses with the P15MZ (2/7) regimen.
Thus, the pharmacokinetics of P and M give PMZ-based
regimens the ﬂexibility to be administered daily or inter-
mittently while preserving some treatment-shortening po-
tential.
The ﬁnding that all PMZ regimens were more active than
the standard daily R10HZ regimen may be explained largely
by the greater rifamycin exposure obtained by substituting P
for R, as a consequence of the former’s longer elimination
half-life. In support of this premise, we found that the AUC168
h/MIC and the percentage of time above MIC were substan-
tially greater for P-based regimens compared to the R-based
regimen. Speciﬁcally, the free drug AUC168 h/MIC values
ranged from 26% to 180% greater for P-based regimens, as
compared to daily R (10 mg/kg), and free drug concentrations
exceeded the MIC for at least 90% of the dosing interval in
each P-based regimen, but for only 60% of the time in the
daily R regimen (Table 3). A similar pharmacodynamic
advantage may be expected in humans because rifamycin
kinetics are similar between mice and humans [23,24]. It is
intriguing that the P7.5MZ (5/7) regimen, which is much more
potent than the control regimen, produced a rifamycin
Cmax/MIC value similar to that of the control regimen;
however the AUC0–168 h/MIC and the percentage of time
above MIC values were signiﬁcantly higher. If, as we surmise,
the sterilizing activities of the rifamycins are linked to the
AUC/MIC and/or the weekly time above MIC (or time above
some other parameter), then one might rightfully question
whether increasing the dose of R to a sufﬁcient level could
lead to similar improvements in sterilizing activity as seen
here with P. While there is great reluctance to use higher
doses of R in intermittent regimens owing to the past
occurrence of serious adverse events [8–10], the use of higher
daily doses of R deserves further evaluation. In the end, the
best rifamycin for daily administration may be the one that is
best tolerated at the highest exposure level. Further explora-
tion of the pharmacodynamics of rifamycin sterilizing activity
would be helpful in this endeavor by identifying the
parameter that correlates best with such activity and the
target exposures necessary for optimal activity. Evaluating the
maximum tolerated dose in humans of both rifampin and
rifapentine would then enable a rational choice of rifamycin
and associated dose for further clinical development.
Table 3. Steady-State Pharmacokinetic and Pharmacodynamic Parameters for Rifapentine and Rifampin in Mice
Regimen Total Drug PK Parameters
a Free Drug PD Parameters
a,b
Cmax (lg/ml) AUC0–168 h (lg-h/ml) Cmax/MIC AUC0–168 h/MIC Percentage of time above
MIC per week (168 h)
R10 (5/7) 13.12 621 6.56 311 60
P15 (2/7) 20.82 1,313 8.69 547 90
P20 (2/7) 27.76 1,751 11.57 730 96
P15 (3/7) 24.45 1,928 10.19 803 100
P7.5 (5/7) 18.05 1,617 7.52 674 100
P10 (5/7) 24.06 2,157 10.03 899 100
P10 (7/7) 24.70 2,710 10.30 1,129 100
aSteady-state PK and PD parameters are based on simulations from single-dose PK data.
bAssumes 2.5% and 17.5% of total serum concentrations of rifapentine and rifampin to be unbound to protein, respectively [6,11,17].
MIC is 0.25 and 0.06 lg/ml for R and P, respectively. AUC0–168 h, area under the serum concentration versus time curve per week (168 h); P, rifapentine; PD, pharmacodynamic; PK,
pharmacokinetic; R, rifampin.
doi:10.1371/journal.pmed.0040344.t003
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Rifapentine and Moxifloxacin for TBThe substitution of M for H also contributes to the
enhanced activity of PMZ regimens over RHZ, as demon-
strated in our second chemotherapeutic study (Figure 2) and
in our previous study of twice-weekly regimens [18]. However,
the substitution of M for H does not contribute as much
treatment-shortening potential as the substitution of P for R.
This important ﬁnding suggests that regimens based solely on
the substitution of P for R also are capable of signiﬁcantly
shortening the duration of treatment, perhaps to 3 mo or less.
The margin of beneﬁt obtained with substituting M for H in a
P-based regimen may be small enough that PHZ regimens
may prove more cost-effective than PMZ regimens in
resource-limited settings.
Our results with daily and intermittent P-based regimens
are especially encouraging in the light of recent clinical
ﬁndings that intermittent treatment with RHZ is less active
than the same treatment administered daily [27–29]. For
example, a recent systematic review of published clinical
trials using 6-mo rifamycin-based treatment regimens found
that treatment with intermittent regimens, with the exception
of a daily initial phase followed by a thrice-weekly continu-
ation phase, was associated with a greater risk of relapse [27].
Abbreviated twice- and thrice-weekly P-based regimens may
provide for highly simpliﬁed treatment regimens that are
more potent than the standard daily rifampin-based regimen.
Several caveats must be considered when extrapolating
these results from the murine model to the treatment of
humans. First and foremost is the reliability with which the
murine model predicts the outcomes of TB chemotherapy in
humans. When care is taken to create a bacillary burden that
is representative of that found in human cavitary TB and to
administer drugs at human-equivalent doses, the mouse
model has a strong track record of predicting the duration
of treatment necessary to attain acceptable cure rates in
human TB with various regimens, including RHZ [23]. More
recently, results in the murine model correlated closely with
the results of a Phase II study to investigate the effect of
substituting M for ethambutol (E) in the standard four-drug
regimen of RHZ plus E [21,30]. Results from additional Phase
II and Phase III studies, some of which are recently concluded
or underway, are expected to shed additional light on
whether the substitution of M for E or H in the standard
four-drug regimen has a beneﬁcial effect, as ﬁrst demon-
strated in the murine model [22].
A second caveat is that the safety and tolerability of the
PMZ regimens studied here have yet to be investigated in
humans. P has been well tolerated when administered at 10
Figure 4. Steady-State Pharmacodynamic Simulations in Mice Treated with Rifapentine Compared with Rifampin
Mice were treated with (A) twice-weekly (2/7) rifapentine 15 mg/kg (dashed line) and 20 mg/kg (solid line); (B) thrice-weekly (3/7) rifapentine 15 mg/kg;
(C) daily (5/7) rifapentine 7.5 mg/kg (dashed line) and 10 mg/kg (solid line); (D) daily (7/7) rifapentine 10 mg/kg; and (e) daily (5/7) rifampin 10 mg/kg.
Rifamycin concentrations are expressed in terms of free drug (2.5% and 17.5% free drug for rifapentine and rifampin, respectively). The free rifamycin
concentration is below the MIC when the curve falls below the solid horizontal line. Pharmacodynamic parameter estimates are shown in Table 3.
doi:10.1371/journal.pmed.0040344.g004
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Rifapentine and Moxifloxacin for TBmg/kg twice-weekly or at 15 and 20 mg/kg once-weekly for 2
mo or more [11,19,20], but there are no published studies
investigating daily or thrice-weekly administration of P or
more frequent administration of 15- and 20-mg/kg doses.
Thus far, daily administration of M in combination with ﬁrst-
line TB drugs for 2 mo appears to be safe and well tolerated
[30]. Treatment for longer durations has also been well
tolerated in anecdotal experiences [31–33].
In conclusion, we have used a well-established murine model
to reevaluate the potential contribution of P to the treatment
of TB. This study has identiﬁed novel regimens that are
dramatically more effective than the standard short-course
RHZ regimen. We believe their greater efﬁcacy is due
primarily to the greater rifamycin exposure obtained when P
is administered more frequently than once-weekly. A more
modest beneﬁcial effect of replacing H with M was also
observed. Because of the prolonged elimination half-life of P,
both intermittent and daily P-based regimens may have the
potential to shorten the duration of treatment, perhaps to 3
mo or less. These results underscore the value of under-
standing antimicrobial pharmacodynamics for new and exist-
ing TB drugs in order to maximize their potential contribution
and support the urgent evaluation of the safety, tolerability,
and efﬁcacy of P-based regimens for the treatment of TB.
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Rifapentine and Moxifloxacin for TBEditors’ Summary
Background. Every year, nearly 9 million people develop tuberculosis—
a bacterial infection most commonly of the lungs—and about 2 million
people die from the disease. Tuberculosis is caused by Mycobacterium
tuberculosis, bacteria that are spread in airborne droplets when people
with active tuberculosis sneeze or cough. Most infected people never
become ill—their immune system successfully contains the infection.
However, the bacteria remain dormant within the body and can cause
disease years later if host immunity declines. Active tuberculosis can be
cured by taking several antibiotics daily (for tuberculosis treatments,
daily may mean five or seven times a week) for at least 6 mo.
Combinations of drugs are needed to prevent the bacteria from
developing resistance to the treatment, but also because of the complex
biology of M. tuberculosis. During active tuberculosis, there are rapidly
multiplying bacteria in the lungs but also less rapidly multiplying and
near-dormant bacteria elsewhere in the body. Effective treatments
contain a ‘‘bactericidal’’ drug such as isoniazid to kill the actively
multiplying bacteria, a drug to kill the less actively multiplying bugs (for
example, pyrazinamide), and a sterilizing drug (the most potent of which
is rifampin) to kill the near-dormant bacteria and thus prevent the
disease from recurring.
Why Was This Study Done? Unfortunately, many patients fail to
complete this treatment because it is long and complicated and because
the drugs may have unpleasant side effects. Poor adherence to
treatment contributes to the emergence of drug resistance and means
that people stay infectious for longer and are more likely to have
relapses. Consequently, it is hampering global efforts to control
tuberculosis. A shorter course of treatment might improve matters, but
many researchers believe that this will require the development of new
drugs and, although there are several promising candidates, it will be
several years before they can be used in patients. In this study, therefore,
the researchers asked whether better use of existing drugs could shorten
treatment times. In particular, they studied tuberculosis in animals to
investigate whether a long-lived rifampin-like drug called rifapentine
combined with moxifloxacin (an alternative to isoniazid) might shorten
treatment times.
What Did the Researchers Do and Find? The researchers used several
different courses (‘‘regimens’’) of treatment containing rifapentine,
moxifloxacin, and pyrazinamide, and the standard daily short-course
regimen containing rifampin, isoniazid, and pyrazinamide to treat mice
infected with M. tuberculosis. For each regimen, they measured its
bactericidal activity by counting how many bacterial colonies could be
grown from the lungs of the mice at specific times during the treatment,
and its sterilizing activity by assessing the proportion of mice with any
live bacteria in their lungs (a culture-positive relapse) after treatment
completion. After 2 mo of treatment, the mice receiving the rifapentine-
and moxifloxacin-containing regimens had negative lung cultures, a
point not reached with the standard regimen until after 4 mo of
treatment. Three months of treatment with daily or thrice-weekly
rifapentine- and moxifloxacin-containing regimens was sufficient to
prevent any culture-positive relapses, whereas the standard daily
regimen had to be continued for 6 mo to achieve cure. Testing of
additional drug combinations revealed that rifapentine is the most
important drug in the new regimen and that simply replacing rifampin
with rifapentine and retaining isoniazid also is sufficient to shorten the
duration of therapy to 3 mo in this experimental model.
What Do These Findings Mean? These findings provide the first
evidence that replacing rifampin with rifapentine might halve the length
of therapy needed to cure tuberculosis. They also indicate that it might
be possible to give the drugs thrice-weekly rather than daily as in the
current therapy. The World Health Organization recommends that all
tuberculosis treatment is supervised (so-called directly observed therapy)
to ensure treatment adherence, so a regimen that requires only three
doses a week for 3 mo would greatly reduce the resources needed to
treat tuberculosis as well as potentially improving treatment adherence.
However, it should be emphasized that the current study is exper-
imental, and there may be important differences between how mice and
people respond to the proposed drug regimens, both in terms of cure
rates and side effects. Nevertheless, these results strongly suggest that
the safety, tolerability, and efficacy of tuberculosis treatment regimens
containing rifapentine and pyrazinamide, combined with either moxi-
floxacin or isoniazid, should be evaluated in people as soon as possible.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040344.
  The MedlinePlus encyclopedia contains a page on tuberculosis (in
English and Spanish)
  The US National Institute of Allergy and Infectious Diseases provides
information on all aspects of tuberculosis
  The US Centers for Disease Control and Prevention provide several fact
sheets and other information resources about tuberculosis, including
information for patients and caregivers about treatment adherence
  The World Health Organization provides a 2007 report on global
tuberculosis control (in English with key findings in French and
Spanish), information on the Stop TB initiative, and a recent bulletin on
tuberculosis treatment (in English with an abstract in French, Spanish,
and Arabic)
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